C‐Myc belongs to the mitogenic signaling pathway downstream of EGFR and may contribute to the limited clinical effectiveness of EGFR inhibitors despite frequent EGFR‐overexpression in HNSCC [36]. This evidence concerns the gene MYC and head and neck squamous cell carcinoma.